Latham & Watkins Advises Bioventus in its Initial Public Offering

A bicoastal deal team advises the life sciences company in the approximately US$104 million offering.

February 11, 2021

Bioventus Inc. has announced the pricing of its initial public offering of 8 million shares of Class A common stock at a public offering price of US$13 per share. The Company’s Class A common stock began trading on the Nasdaq Global Select Market under the symbol “BVS.”

Latham & Watkins LLP represents Bioventus, Inc. in the offering with a corporate team led by Boston/New York partner Wesley Holmes and Orange County/New York partner Charles Ruck, with associates Katie Lovejoy, Jessica Lim, Jonathan Hernandez, and Hera Liao. Advice was also provided on tax matters by Washington, D.C. partner Andrea Ramezan-Jackson, with associate Eli McCrain; on benefits and compensation matters by New York counsel Rifka Singer, with associate Daniel Gocek; on intellectual property matters by Bay Area partner Judith Hasko, with associate Seth Appiah-Opoku; on public company representation matters by New York partner Dennis Craythorn, with associate Kate Pritchard; on FDA regulatory matters by Washington, D.C. partner Elizabeth Richards, with associate Barrett Tenbarge; and on healthcare regulatory matters by Washington, D.C. partners Stuart Kurlander and Eric Greig.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.